TY - JOUR
T1 - Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels
AU - Du, Dongning
AU - Zhu, Xuejuan
AU - Kuno, Atsushi
AU - Matsuda, Atsushi
AU - Tsuruno, Chikayuki
AU - Yu, Demin
AU - Zhang, Yan
AU - Ikehara, Yuzuru
AU - Tanaka, Yasuhito
AU - Zhang, Xinxin
AU - Narimatsu, Hisashi
PY - 2012/11/12
Y1 - 2012/11/12
N2 - Background: FibroScan is one of the noninvasive techniques based on the transient elastography that can assess the progression of liver fibrosis in chronic hepatitis patients in daily clinical practice. Recently, LecT-Hepa was validated as a serological glycomarker correlating well with the fibrosis stage determined by liver biopsy, and was superior to many other noninvasive biochemical markers and tests. We compared the reliability of LecT-Hepa with that of FibroScan for evaluation of liver fibrosis. Methods: The effects of increased alanine aminotransferase (ALT) activities on LecT-Hepa and FibroScan were investigated. Results: The areas under the receiver-operating characteristic curves, sensitivity and specificity for detecting cirrhosis, which is one of the outcomes of fibrosis estimation, were 0.82, 72.5% and 78.2% of LecT-Hepa, 0.85, 87.0% and 74.1% of FibroScan; these did not differ significantly. The count distribution of LecT-Hepa in non-cirrhosis group or cirrhosis group did not differ between the patients grouped according to their ALT levels, whereas that of FibroScan was substantially affected. Conclusion: LecT-Hepa was confirmed as a reliable noninvasive test for the evaluation of liver fibrosis in hepatitis B virus-infected patients with comparable performance to that of FibroScan and proved to be unaffected by inflammation.
AB - Background: FibroScan is one of the noninvasive techniques based on the transient elastography that can assess the progression of liver fibrosis in chronic hepatitis patients in daily clinical practice. Recently, LecT-Hepa was validated as a serological glycomarker correlating well with the fibrosis stage determined by liver biopsy, and was superior to many other noninvasive biochemical markers and tests. We compared the reliability of LecT-Hepa with that of FibroScan for evaluation of liver fibrosis. Methods: The effects of increased alanine aminotransferase (ALT) activities on LecT-Hepa and FibroScan were investigated. Results: The areas under the receiver-operating characteristic curves, sensitivity and specificity for detecting cirrhosis, which is one of the outcomes of fibrosis estimation, were 0.82, 72.5% and 78.2% of LecT-Hepa, 0.85, 87.0% and 74.1% of FibroScan; these did not differ significantly. The count distribution of LecT-Hepa in non-cirrhosis group or cirrhosis group did not differ between the patients grouped according to their ALT levels, whereas that of FibroScan was substantially affected. Conclusion: LecT-Hepa was confirmed as a reliable noninvasive test for the evaluation of liver fibrosis in hepatitis B virus-infected patients with comparable performance to that of FibroScan and proved to be unaffected by inflammation.
KW - Alanine aminotransferase
KW - Cirrhosis
KW - Glycomarker
KW - Hepatitis B
KW - Liver fibrosis
UR - http://www.scopus.com/inward/record.url?scp=84864490721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864490721&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.07.005
DO - 10.1016/j.cca.2012.07.005
M3 - Article
C2 - 22796373
AN - SCOPUS:84864490721
SN - 0009-8981
VL - 413
SP - 1796
EP - 1799
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 21-23
ER -
